Navigation Links
Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
Date:8/24/2009

NATICK, Mass., Aug. 24 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing final results from the landmark MADIT-CRT trial on Tuesday, September 1, at 8:00 a.m. ET / 2:00 p.m. Barcelona time.

The call will be hosted by Ray Elliott, President and Chief Executive Officer; Fred Colen, Executive Vice President and Group President, Cardiac Rhythm Management; and Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial.

The final results from the MADIT-CRT trial will be presented during a Hot Line session at the European Society of Cardiology (ESC) Congress in Barcelona and published in a major peer-reviewed journal. The Company plans to issue a press release simultaneous with an ESC Hot Line press conference to be held in Barcelona on September 1.

The live webcast and archived replay of this call will be available at www.bostonscientific.com in the Investor Relations section. The webcast is also being distributed over Thomson Financial's Investor Distribution Network via two locations: www.earnings.com, which is accessible to the public, and www.streetevents.com, a password-protected event management site.

To ensure a timely connection to the live webcast it is recommended that users register at least 15 minutes before the webcast begins. A replay of the webcast will begin at approximately 11:00 a.m. ET on September 1 and will be available for one year.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

    CONTACT:  Paul Donovan
              508-650-8541
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
2. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
3. Boston Scientific to Participate in Wachovia Conference
4. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
5. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
6. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
7. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
8. Boston Scientific Welcomes Launch of Syntax Score Website
9. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
10. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
11. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016  In ... Society of Hematology (ASH) Annual Meeting and Exposition in ... advanced biomedical engineering methods to improve the delivery of ... conditions. These new methods are designed to carry therapies ... are needed most, which could provide a substantial advantage ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... tube systems for North American hospitals, will present its chain-of-custody solution for tracking ... Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):